HCV Advocate LogoHCV Advocate Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference reports
News Articles
HCV Advocate Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
Bookmark and Share
News Review

Top News
from EASL 2014

EASL 2014: New treatment regimens for cirrhotic, HCV patients highlighted
May 1

EASL 2014: Dual therapy of daclatasvir and asunaprevir produces SVR12 in phase 3 trial
April 24

EASL 2014: Patients ineligible for HCV treatment due to age, comorbidities
April 20

EASL 2014: Research presented on transplant patients with recurring HCV
April 19

EASL 2014: ION 2: Longer sofosbuvir/ledipasvir treatment may be unnecessary in previous failures
April 16

EASL 2014: Treatment as Prevention for Drug Users Could Slash HCV Prevalence
April 12

EASL 2014: Merck's Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
April 12

EASL 2014: AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress™
April 12

EASL 2014: AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™
April 12

EASL 2014: Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)
April 12

EASL 2014: Sofosbuvir + Ledipasvir Produces Early Cure for 100% of HIV/HCV Coinfected Patients
April 11

EASL 2014: Viral hepatitis more deadly than HIV in Europe
April 11

Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection
April 11

EASL 2014: Gilead's Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
April 11

EASL 2014: Cure Rate for Experimental Hepatitis C Drug Tops 95 Percent
April 10

EASL 2014: Bristol-Myers hepatitis C treatment cures up to 90 percent: study
April 10

EASL 2014: Merck Data Show Potent Rival to Gilead's Hepatitis C Pill
April 10

EASL 2014: Global response to hepatitis C hangs on access to new oral drugs
April 10

EASL 2014: Merck hepatitis C drugs shine in easier to treat patients: study
April 10

EASL publishes online recommendations on the management of hepatitis C
April 9


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home

Hepatitis C Support Project

© 2014 Hepatitis C Support Project

Medical  Writers' Circle
Fact Sheets